5 most recent filings and news items mentioning INBS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/INBS/news?limit=20"
Pull INBS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayIntelligent Bio Solutions completed a usability study for its Intelligent Fingerprinting Drug Screening System confirming effective use by non-specialist operators. This milestone aligns with the company's plan to submit a 510(k) in Q3 2026 to enter the U.S. market.
View filing at SEC.gov →Intelligent Bio Solutions has completed an interference study to validate the accuracy of its drug screening system under real-world conditions, solidifying plans to submit the FDA 510(k) package in the second half of 2026 to enter the U.S. market.
View filing at SEC.gov →The company resolved all cybersecurity and software review items, de-risking the regulatory path for its fingerprint drug test. The move positions INBS for U.S. market entry into a multi-billion-dollar industry.
View filing at SEC.gov →Intelligent Bio Solutions completed precision testing of its fingerprint drug screen across three sites to support its FDA 510(k) submission for the U.S. opiate detection market, valued at over $1 billion.
View filing at SEC.gov →Intelligent Bio Solutions initiated a clinical study with CenExel to validate its Intelligent Fingerprinting Drug Screening System for FDA clearance, with enrollment completion expected by July 2026. The study demonstrates real-world usability by non-specialized personnel, a key
View filing at SEC.gov →